Po62
To determine the long-term disease-free survival, long-term toxicity, and effect on health-related quality of life of a two-fraction regimen of high-dose-rate (HDR) prostate brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Marc Gaudet, Raphael Rezkallah, Pierre-Yves McLaughlin, Alain Haddad Source Type: research
Po63
Optimizing Prostate Cancer Treatment in Men with Advanced Local disease (OPTiMAL) is a single-arm phase II study targeted towards unfavourable risk patients. As a successor to the largest randomized clinical trial (ASCENDE) comparing low-dose-rate prostate brachytherapy (LDR-PB) boost to external beam radiation therapy (EBRT) boost for prostate cancer (PCa) treatment, this study is designed to continue the use of the LDR-PB boost that resulted in high levels of biochemical progression-free survival (b-PFS) in ASCENDE while also aiming to reduce adverse side effects by lowering the overall dose and also limiting high dose r...
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Tajwar Abrar Aleef, Ingrid T. Spadinger, Shahed K. Mohammed, Septimiu E. Salcudean, S. Sara Mahdavi, William James Morris, Michael Peacock Source Type: research
Po64
When utilizing a hydrogel spacer for HDR prostate brachytherapy, hydrogel can be inserted at time of HDR catheter implantation or on a separate visit prior to HDR. The insertion of gel at time of HDR can be more difficult due to interference from the perineal template with imbedded catheters. To assess whether time of hydrogel placement impacted its insertion geometry, we compared patients who had hydrogel placed by a single provider at either the time of HDR brachytherapy (templated insertion - TI) or in advance of prostate stereotactic body radiation therapy (non-templated insertion - NTI). (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Shyamal Patel, Dilini Pinnaduwage, Nitika Thawani, Stephen Sorensen, Shyam Jani, Steven Ellefson, Aidnag Diaz, Shiv Srivastava Source Type: research
Po65
This retrospective study compares high dose rate brachytherapy (HDR BT) monotherapy against HDR BT and external beam radiation therapy (EBRT), with and without androgen deprivation therapy (ADT), to determine non-inferiority of HDR BT alone in the treatment of unfavorable intermediate risk (UIR) prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Eulanca Yuka Liu, Eric Lin, Puja Venkat, Alan Lee, Jay Shiao, Andrew Wong, Austin Yu, Mary Ann Hagio, Sang-June Park, D. Jeffrey Demanes, Albert J. Chang Source Type: research
Po66
Urethra complications continues to remain a major concern for patients receiving ultrasound-guided high-dose-rate (HDR) prostate brachytherapy. One way to effectively minimize the incidence would be to avoid high doses in the organ, but this is difficult to achieve while ensuring adequate target coverage. Solutions with intensity modulated brachytherapy (IMBT) design concept, such as rotating shield brachytherapy (RSBT), has achieved this ideal dosimetry on-paper but its clinical implementation is challenging due to moving mechanisms that require high precision and the use of non-conventional HDR sources such as 153Gd, ele...
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Moeen Meftahi, Richard L.J. Qiu, Pretesh Patel, William Y. Song, Xiaofeng Yang Source Type: research
Po67
To evaluate the dosimetric outcomes of focal salvage low dose rate (LDR) brachytherapy for biopsy proven local recurrence of prostate cancer after definitive external beam radiation therapy (EBRT) utilizing an MR-guided transperineal mapping biopsy to delineate the target volume. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Tyler E. Gutschenritter, Anthony Pham, Homayon Parsai, Joe Bradlo, Merriah Montague, Sarah Reith, Justin Bell, Rosanna Mangibin, Richard Alex Hsi Source Type: research
Po68
Data from the Focal Lesion Ablative Microboost in Prostate Cancer (FLAME) trial suggests a dose response for achieving local control of the dominant intraprostatic lesion (DIL). They reported a dose of ≥ 85 Gy achieves a 7-year probability of local control of almost 100%. Investigations using brachytherapy to microboost the DIL have been ongoing for decades and deliver a much higher dose than 85 Gy. Considering this, the purpose of this study is to perform a systematic review on brachytherapy mi croboost of the DIL to evaluate clinical outcomes and toxicities with this treatment approach. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Mehdi Kazemi, Andrew Barsoum, Mitchell Kamrava Source Type: research
Po69
Standard of care for localized prostate cancer is either surgical or radiotherapeutic. While total gland ablation was intended, recent efforts of certain institutions using cryotherapy or HIFU (High-Intensity Focused Ultrasound) have explored the efficacy of focal therapy for select patients. Diagnostic technology has evolved and improved the ability and accuracy to identify tumor extent and location. This analysis investigates low-dose-rate (LDR) focal prostate brachytherapy PSA outcomes by demonstrating impact and thus correlation with focal target volume. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Brian J. Moran, Roksana Tech, Jessica Manzella Source Type: research
Po70
The purpose of this study was to evaluate the gastrointestinal toxicity profile of a combined modality treatment for prostate cancer, consisting of external beam radiation (EBRT) and brachytherapy with rectal spacer hydrogel. The study aimed to assess the quality of prostate brachytherapy implants with spacer hydrogel in place and assess gastrointestinal complications in a real-world dataset. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Parisa Shamsesfandabadi, Hirsch Matani, John Berzanske, Kyung Lim Yun, Michelle Shupe, Lauren Hindman, Yue Yin, Abigail Dare, Daniel Pavord, Sushil Beriwal, Rodney E. Wegner, Zachary D. Horne Source Type: research
Po71
High-Dose-Rate Brachytherapy (HDR-BT) is an effective yet under-utilized treatment option for localized prostate cancer. Many studies have shown excellent long-term biochemical-failure-free survival outcomes with limited toxicity from HDR-BT as monotherapy for low- or intermediate-risk prostate cancer. However, due to higher start-up costs, less reimbursement, and inadequacy in residency training, far fewer radiation facilities are offering BT than external beam radiation (EBRT). Here, we performed a single-center, retrospective cohort study to evaluate the travel burdens put on patients who received BT as monotherapy at o...
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Hong Zhang, Catherine Liu Source Type: research
Po72
Radiation management literature focused on optimizing care for patients with intellectual disability is sparse. We add our experience to the literature with the goal to improve care to this vulnerable patient population. To this end, we report three cases of prostate cancer in patients with limited cognition who were treated with low dose rate (LDR) prostate brachytherapy to highlight an effective strategy to deliver optimal care to this group of patients. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Evans Amoah, Jeremiah Johnson, Stephen Strup, Ali Soleimani-Meigooni, William St. Clair Source Type: research
Po73
To identify a predictive factor associated with local recurrence in prostate cancer patients receiving HDR brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Wiwatchai Sittiwong, Pittaya Dankulchai Source Type: research
Po74
Brachytherapy has established itself as an effective method for cancer treatment of many different body sites where a radioactive source can be placed in or in vicinity of the disease. Brachytherapy provides the most conformal dose distribution and is least affected by involuntary body motions as compared to external radiotherapy. Promising results have been reported for local control and treatment of prostate cancer. Despite the maturity of brachytherapy, common dose calculations are based on several simplifications that can degrade the accuracy of dosimetry. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Milad Payandeh, Faraz Kalantari, Mahdi Sadeghi, Gary Lewis, Somayeh Gholami Source Type: research
Po75
The purpose of this study is to determine the efficacy of high dose-rate brachytherapy as a single modality treatment in patients with low and intermediate risk prostate cancer in a community setting. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Fred J. Schnell, Steven Schnell, Mark Quinn Source Type: research
Physics Posters PO76
We developed a new concept of a mixed reality (MR)-guided intraoperative visual support system for inserting an interstitial needle applicator (needle) in combined intracavitary and interstitial brachytherapy (IC/IS-BT) for cervical cancer and evaluated its feasibility. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Ryuta Hirai, Masatsugu Hariu, Tomohiro Ohta, Mitsunobu Igari, Yu Kumazaki, Misaki Iino, Tomomi Aoshika, Yasuhiro Ryuno, Satoshi Saito, Takanori Abe, Shin-ei Noda, Shingo Kato Source Type: research
